Comparative Study of MRI Biomarkers in the Substantia Nigra to Discriminate Idiopathic Parkinson Disease

References

1. 1.↵
   2. Fearnley JM,
   3. Lees AJ

   . Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283–301 doi:10.1093/brain/114.5.2283 pmid:1933245

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Du G,
   3. Lewis MM,
   4. Styner M, et al

   . Combined R2* and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord 2011;26:1627–32 doi:10.1002/mds.23643 pmid:21618607

   CrossRefPubMed
3. 3.↵
   2. Péran P,
   3. Cherubini A,
   4. Assogna F, et al

   . Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010;133:3423–33 doi:10.1093/brain/awq212 pmid:20736190

   CrossRefPubMedWeb of Science
4. 4.↵
   2. Vaillancourt DE,
   3. Spraker MB,
   4. Prodoehl J, et al

   . High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009;72:1378–84 doi:10.1212/01.wnl.0000340982.01727.6e pmid:19129507

   Abstract/FREE Full Text
5. 5.↵
   2. Schwarz ST,
   3. Abaei M,
   4. Gontu V, et al

   . Diffusion tensor imaging of nigral degeneration in Parkinson's disease: a region-of-interest and voxel-based study at 3 T and systematic review with meta-analysis. Neuroimage Clin 2013;3:481–88 doi:10.1016/j.nicl.2013.10.006 pmid:24273730

   CrossRefPubMed
6. 6.↵
   2. Barbosa JH,
   3. Santos AC,
   4. Tumas V, et al

   . Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2. Magn Reson Imaging 2015;33:559–65 doi:10.1016/j.mri.2015.02.021 pmid:25721997

   CrossRefPubMed
7. 7.↵
   2. Sasaki M,
   3. Shibata E,
   4. Tohyama K, et al

   . Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neuroreport 2006;17:1215–18 doi:10.1097/01.wnr.0000227984.84927.a7 pmid:16837857

   CrossRefPubMedWeb of Science
8. 8.↵
   2. Naidich TP,
   3. Duvernoy HM

   . Duvernoy's Atlas of the Human Brain Stem and Cerebellum: High-Field MRI, Surface Anatomy, Internal Structure, Vascularization and 3D Sectional Anatomy. New York: Springer-Verlag; 2009
9. 9.↵
   2. Schwarz ST,
   3. Rittman T,
   4. Gontu V, et al

   . T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Mov Disord 2011;26:1633–38 doi:10.1002/mds.23722 pmid:21491489

   CrossRefPubMed
10. 10.↵
    2. Reimão S,
    3. Pita Lobo P,
    4. Neutel D, et al

    . Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients. Eur J Neurol 2015;22:540–46 doi:10.1111/ene.12613 pmid:25534480

    CrossRefPubMed
11. 11.↵
    2. Haber SN

    . The primate basal ganglia: parallel and integrative networks. J Chem Neuroanat 2003;26:317–30 doi:10.1016/j.jchemneu.2003.10.003 pmid:14729134

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Jellinger KA

    . Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord 2012;27:8–30 doi:10.1002/mds.23795 pmid:22081500

    CrossRefPubMed
13. 13.↵
    2. Blazejewska AI,
    3. Schwarz ST,
    4. Pitiot A, et al

    . Visualization of nigrosome 1 and its loss in PD: pathoanatomical correlation and in vivo 7 T MRI. Neurology 2013;81:534–40 doi:10.1212/WNL.0b013e31829e6fd2 pmid:23843466

    Abstract/FREE Full Text
14. 14.↵
    2. Reiter E,
    3. Mueller C,
    4. Pinter B, et al

    . Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. Mov Disord 2015;30:1068–76 doi:10.1002/mds.26171 pmid:25773707

    CrossRefPubMed
15. 15.↵
    2. Reimão S,
    3. Pita Lobo P,
    4. Neutel D, et al

    . Quantitative analysis versus visual assessment of neuromelanin MR imaging for the diagnosis of Parkinson's disease. J Parkinsons Dis 2015;5:561–67 doi:10.3233/JPD-150551 pmid:26406136

    CrossRefPubMed
16. 16.↵
    2. Ohtsuka C,
    3. Sasaki M,
    4. Konno K, et al

    . Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord 2014;20:755–60 doi:10.1016/j.parkreldis.2014.04.005 pmid:24768616

    CrossRefPubMed
17. 17.↵
    2. Castellanos G,
    3. Fernández-Seara MA,
    4. Lorenzo-Betancor O, et al

    . Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease. Mov Disord 2015;30:945–52 doi:10.1002/mds.26201 pmid:25772492

    CrossRefPubMed
18. 18.↵
    2. Yushkevich PA,
    3. Piven J,
    4. Hazlett HC, et al

    . User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage 2006;31:1116–28 doi:10.1016/j.neuroimage.2006.01.015 pmid:16545965

    CrossRefPubMedWeb of Science
19. 19.↵
    2. Langley J,
    3. Huddleston DE,
    4. Merritt M, et al

    . Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited. Hum Brain Mapp 2016;37:2547–56 doi:10.1002/hbm.23192 pmid:27029026

    CrossRefPubMed
20. 20.↵
    2. Schwarz ST,
    3. Afzal M,
    4. Morgan PS, et al

    . The ‘swallow tail’ appearance of the healthy nigrosome: a new accurate test of Parkinson's disease—a case-control and retrospective cross-sectional MRI study at 3T. PLoS One 2014;9:e93814 doi:10.1371/journal.pone.0093814 pmid:24710392

    CrossRefPubMed
21. 21.↵
    2. Nichols TE,
    3. Holmes AP

    . Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp 2002;15:1–25 doi:10.1002/hbm.1058 pmid:11747097

    CrossRefPubMedWeb of Science
22. 22.↵
    2. Braak H,
    3. Del Tredici K,
    4. Rüb U, et al

    . Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197–211 doi:10.1016/S0197-4580(02)00065-9 pmid:12498954

    CrossRefPubMedWeb of Science
23. 23.↵
    2. Kastner A,
    3. Hirsch EC,
    4. Lejeune O, et al

    . Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem 1992;59:1080–89 doi:10.1111/j.1471-4159.1992.tb08350.x pmid:1494900

    CrossRefPubMedWeb of Science
24. 24.↵
    2. Kashihara K,
    3. Shinya T,
    4. Higaki F

    . Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease. J Clin Neurosci 2011;18:1093–96 doi:10.1016/j.jocn.2010.08.043 pmid:21719292

    CrossRefPubMed
25. 25.↵
    2. Kempster PA,
    3. Gibb WR,
    4. Stern GM, et al

    . Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. J Neurol Neurosurg Psychiatry 1989;52:72–76 doi:10.1136/jnnp.52.1.72 pmid:2709038

    Abstract/FREE Full Text
26. 26.↵
    2. Menke RA,
    3. Scholz J,
    4. Miller KL, et al

    . MRI characteristics of the substantia nigra in Parkinson's disease: a combined quantitative T1 and DTI study. Neuroimage 2009;47:435–41 doi:10.1016/j.neuroimage.2009.05.017 pmid:19447183

    CrossRefPubMedWeb of Science
27. 27.↵
    2. Wang JJ,
    3. Lin WY,
    4. Lu CS, et al

    . Parkinson disease: diagnostic utility of diffusion kurtosis imaging. Radiology 2011;261:210–17 doi:10.1148/radiol.11102277 pmid:21771952

    CrossRefPubMed
28. 28.↵
    2. Ofori E,
    3. Pasternak O,
    4. Planetta PJ, et al

    . Increased free water in the substantia nigra of Parkinson's disease: a single-site and multi-site study. Neurobiol Aging 2015;36:1097–104 doi:10.1016/j.neurobiolaging.2014.10.029 pmid:25467638

    CrossRefPubMed
29. 29.↵
    2. Tosk JM,
    3. Holshouser BA,
    4. Aloia RC, et al

    . Effects of the interaction between ferric iron and L-dopa melanin on T1 and T2 relaxation times determined by magnetic resonance imaging. Magn Reson Med 1992;26:40–45 doi:10.1002/mrm.1910260105 pmid:1625565

    CrossRefPubMed
30. 30.↵
    2. Kwon DH,
    3. Kim JM,
    4. Oh SH, et al

    . Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 2012;71:267–77 doi:10.1002/ana.22592 pmid:22367998

    CrossRefPubMed
31. 31.↵
    2. Cosottini M,
    3. Frosini D,
    4. Pesaresi I, et al

    . Comparison of 3T and 7T susceptibility-weighted angiography of the substantia nigra in diagnosing Parkinson disease. AJNR Am J Neuroradiol 2015;36:461–66 doi:10.3174/ajnr.A4158 pmid:25376811

    Abstract/FREE Full Text
32. 32.↵
    2. Mahlknecht P,
    3. Krismer F,
    4. Poewe W, et al

    . Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease. Mov Disord 2017;32:619–23 doi:10.1002/mds.26932 pmid:28151553

    CrossRefPubMed
33. 33.↵
    2. Michaeli S,
    3. Oz G,
    4. Sorce DJ, et al

    . Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. Mov Disord 2007;22:334–40 doi:10.1002/mds.21227 pmid:17149719

    CrossRefPubMed
34. 34.↵
    2. Esterhammer R,
    3. Seppi K,
    4. Reiter E, et al

    . Potential of diffusion tensor imaging and relaxometry for the detection of specific pathological alterations in Parkinson's Disease (PD). PLoS One 2015;10:e0145493 doi:10.1371/journal.pone.0145493 pmid:26713760

    CrossRefPubMed
35. 35.↵
    2. Schwarz J,
    3. Weis S,
    4. Kraft E, et al

    . Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 1996;60:98–101 doi:10.1136/jnnp.60.1.98 pmid:8558163

    Abstract/FREE Full Text
36. 36.↵
    2. Pujol J,
    3. Junqué C,
    4. Vendrell P, et al

    . Reduction of the substantia nigra width and motor decline in aging and Parkinson's disease. Arch Neurol 1992;49:1119–22 doi:10.1001/archneur.1992.00530350033015 pmid:1444876

    CrossRefPubMed